STOCK TITAN

Erasca to Present at the 2022 Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, will present at the 2022 Jefferies Healthcare Conference on June 10, 2022, at 8:00 AM ET in New York. CEO Jonathan E. Lim and CFO David M. Chacko will represent the company and participate in one-on-one investor meetings. A live webcast and an archived replay of the presentation will be available online, continuing until September 10, 2022. Erasca’s mission is to erase cancer through innovative therapies targeting the RAS/MAPK pathway.

Positive
  • None.
Negative
  • None.

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 2022 Jefferies Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a presentation at 8:00 am Eastern Time on Friday, June 10, 2022, at the Marriott Marquis in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

A live webcast of the event will be available online at webcast/jefferies. An archived replay of the event will be available until September 10, 2022, following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.


FAQ

What is the date of Erasca's presentation at the Jefferies Healthcare Conference?

Erasca will present at the Jefferies Healthcare Conference on June 10, 2022.

Who will represent Erasca at the 2022 Jefferies Healthcare Conference?

Jonathan E. Lim, CEO, and David M. Chacko, CFO, will represent Erasca.

What time is Erasca's presentation at the Jefferies Healthcare Conference?

Erasca's presentation is scheduled for 8:00 AM ET.

Where can I watch the Erasca presentation from the Jefferies Healthcare Conference?

A live webcast of the presentation will be available online on Erasca's official website.

How long will the archived replay of Erasca's presentation be available?

The archived replay will be available until September 10, 2022.

What is Erasca's mission in oncology?

Erasca's mission is to erase cancer by developing therapies targeting the RAS/MAPK pathway.

Erasca, Inc.

NASDAQ:ERAS

ERAS Rankings

ERAS Latest News

ERAS Stock Data

718.13M
228.31M
12.39%
87.01%
11.67%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO